CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 458 enrolled
Drug / intervention
ruxolitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04530344
NCT04530344Phase 3Completed
CompareCT.gov

A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Incyte Corporation·interventional·Posted Aug 28, 2020·Updated Aug 14, 2025

In Brief

A Phase 3 clinical trial evaluating ruxolitinib and Vehicle for Vitiligo. Completed, enrolled 458 participants across 84 sites in 8 countries.

Detailed Summary

The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesBulgaria, Canada, France, Germany, Netherlands, Poland, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedAug 28, 2020
Enrollment StartSep 24, 2020
Primary CompletionNov 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.8 years ago

Interventions

ruxolitinibdrug

ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.

Vehicledrug

Vehicle cream is a topical formulation applied as a thin film to affected areas.